四维扩展访问程序
EBV,CMV,腺病毒或BK病毒感染的多病毒特异性细胞毒性T淋巴细胞的扩展使用使用。
This Expanded Access Program (EAP) allows qualified physicians within Texas to obtain access to multivirus-specific cytotoxic T lymphocytes (VSTs) developed under Baylor College of Medicine's TETRAVI program (NCT04013802) for the treatment of persistent or recurrent infections with EBV, CMV, adenovirus, or BK virus in pediatric patients being treated in Texas who have received allogeneic stem cell transplants and have no other suitable therapeutic options.
研究概览
地位
地位
条件
条件
干预/治疗
干预/治疗
详细说明
This EAP is limited to pediatric patients being treated in the State of Texas. In this program, Baylor College of Medicine's Center for Cell and Gene Therapy (CAGT) will provide applicable physicians with copies of a template protocol and consent form, allowing each site to establish its own single-patient expanded access protocol. Baylor will also issue a Letter of Authorization (LOA) to cross-reference its own IND. This LOA will accompany the local site's submission to the FDA. The VSTs will be provided to eligible patients through this mechanism upon IRB and FDA approval of the treating site's individual patient protocol.
The aim is to enable access to off-the-shelf partially HLA-matched virus-specific T cells for pediatric patients located in Texas (USA) with limited treatment options due to persistent or resistant viral infections post-transplant.
研究类型
研究类型
扩展访问类型
扩展访问类型
- 个体患者:允许患有严重疾病或病症但无法参加临床试验的单个患者获得药物或生物制品尚未获得 FDA 批准。此类别还包括紧急情况下的访问。
- 中等规模人群:允许不止一名患者(但通常比通过治疗 IND/协议的患者少)访问未经 FDA 批准的药物或生物制品。当多名患有相同疾病或病症的患者寻求获得 FDA 尚未批准的特定药物或生物制品时,将使用这种类型的扩展访问。
- 治疗 IND/协议 :允许大量广泛的人群获得未经 FDA 批准的药物或生物制品。仅当产品已针对与扩展访问用途相同的用途进行营销开发时,才能提供此类扩展访问。
- 个体患者
- 治疗 IND/方案
联系人和位置
学习联系方式
学习联系方式
- 姓名:John Craddock, MD
- 电话号码:(832) 824-1583
- 邮箱:jacraddo@txch.org
研究联系人备份
- 姓名:Emily Jobe
- 电话号码:(832) 824-4103
- 邮箱:edjobe@texaschildrens.org
参与标准
资格标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients <18 years of age.
- Patients who have undergone myeloablative or non-myeloablative allogeneic HSCT or CAR T therapy in the Sate of Texas (USA).
- Have persistent, increasing, or recurrent infections with EBV, CMV, adenovirus, or BK virus despite standard treatment.
- Treating physician must be based in Texas.
- Must obtain IRB approval and submit a protocol to FDA with Letter of Authorization from Baylor.
Exclusion Criteria:
- Patients with active uncontrolled infections unrelated to the viruses mentioned.
- Use of certain immunosuppressive agents within 28 days.
- Serious uncontrolled medical conditions or relapse of underlying disease.
学习计划
研究是如何设计的?
合作者和调查者
调查人员
调查人员
- 学习椅:John Craddock, MD、Baylor College of Medicine
研究记录日期
研究注册日期
首次提交
首次提交
首先提交符合 QC 标准的
首先提交符合 QC 标准的
首次发布 (实际的)
首次发布
研究记录更新
最后更新发布 (实际的)
最后更新发布
上次提交的符合 QC 标准的更新
上次提交的符合 QC 标准的更新
最后验证
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.